Global therapeutic pipeline for non-oncology orphan drug programs by company 2019

This graph shows the number of orphan designated drugs currently being developed by emerging therapeutic companies in the U.S., as of April 2019. As of this time, of the 612 non-oncologic orphan programs being developed, almost half were in Phase II of development.

Number of non-oncology orphan designated products currently being developed worldwide by company type as of April 2019

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

$39 $59 per month *
in the first 12 months
33% discount until May 31st
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

2019

Region

Worldwide

Survey time period

as of April 2019

Special properties

orphan programs excluding oncology

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* Prices do not include sales tax.

Statistics on "Orphan drugs"

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.